• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [23537 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2022     National Institute for Health and Care Excellence (NICE) Aortic remodelling hybrid stent insertion during surgical repair of an acute type A aortic dissection. NICE interventional procedures guidance 733
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: evaluation of Afstyla™ (rFVIII) – type A hemophilia]
2022     Agency for Care Effectiveness (ACE) Bevacizumab biosimilar for treating different types of cancers
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (adenocarcinoma of the stomach, the gastro-oesophageal junction or the oesophagus) - 2nd Addendum to Commission A21-146]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Selpercatinib (thyroid cancer) - Benefit assessment according to §35a Social Code Book V]
2022     National Institute for Health and Care Excellence (NICE) Transcatheter tricuspid valve annuloplasty for tricuspid regurgitation. NICE interventional procedures guidance 730
2022     NIHR Health Technology Assessment programme The CRASH-3 Trial: Tranexamic acid for the treatment of significant traumatic brain injury
2022     Penn Medicine Center for Evidence-based Practice (CEP) Restrictive red blood cell (RBC) transfusion thresholds: update
2022     Agency for Care Effectiveness (ACE) Tofacitinib, ustekinumab and vedolizumab for treating inflammatory bowel disease
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ertugliflozin (type 2 diabetes mellitus) - Addendum to Commission A21-158]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Systematic search for registries in the therapeutic indication haemophilia B (congenital factor IX deficiency)]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12F: Anti-D prophylaxis: evidence report for the S3 guideline on abortion in the first trimester]
2022     National Institute for Health and Care Excellence (NICE) Transcatheter tricuspid valve leaflet repair for tricuspid regurgitation. NICE interventional procedures guidance 731
2022     NIHR Health Technology Assessment programme Dynamic contrast-enhanced CT compared with positron emission tomography CT to characterise solitary pulmonary nodules: the SPUtNIk diagnostic accuracy study and economic modelling
2022     Agency for Care Effectiveness (ACE) Sitagliptin for treating type 2 diabetes mellitus
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sacituzumab govitecan (breast cancer) - Addendum to Commission A21-154]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Systematic search for registries in the therapeutic indication of acute lymphoblastic leukaemia]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12G: Routine follow-up examination: evidence report for the S3 guideline on abortion in the first trimester]
2022     National Institute for Health and Care Excellence (NICE) Vertebral body tethering for idiopathic scoliosis in children and young people. NICE interventional procedures guidance 728
2022     Swiss Federal Office of Public Health (FOPH) Denosumab (Prolia®) for the treatment of osteoporosis
2022     NIHR Public Health Research (PHR) programme E-health interventions targeting STIs, sexual risk, substance use and mental health among men who have sex with men: four systematic reviews
2022     Agency for Care Effectiveness (ACE) Emicizumab prophylaxis for patients with haemophilia A
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mepolizumab (chronic rhinosinusitis with nasal polyposis) - Addendum to Commission A21-150]
2022     National Institute for Health and Care Excellence (NICE) Nerve graft for corneal denervation. NICE interventional procedures guidance 729
2022     Swiss Federal Office of Public Health (FOPH) Trimonthly vs. monthly use of bone-targeted agents in patients with bone metastases and multiple myeloma
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: organization of medical care and services in long-term care facilities]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pharmacotherapeutic interventions - Evidence report on the S3 guideline "Cannabis-related disorders"]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tonsillectomy or tonsillotomy: evidence report for the S3 guideline on treatment of inflammatory diseases of the palatine tonsils/tonsillitis]
2022     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Folate testing. [Protocol]
2022     National Institute for Health and Care Excellence (NICE) Synthetic cartilage implant insertion for first metatarsophalangeal joint osteoarthritis (hallux rigidus). NICE interventional procedures guidance 727
2022     Swiss Federal Office of Public Health (FOPH) Sedative-hypnotic drugs for the treatment of primary chronic insomnia disorder
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: a look at Québec’s family medicine groups and a proposal to segment the population to support continuous quality improvement approaches based on health needs]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mepolizumab (eosinophilic granulomatosis with polyangiitis) - Addendum to Commission A21-151]
2022     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Revascularisation versus optimal medical therapy (OMT) for the treatment of chronic coronary syndrome (CCS). [Protocol]
2022     National Institute for Health and Care Excellence (NICE) Endoanchoring systems in endovascular aortic aneurysm repair. NICE interventional procedures guidance 725
2022     Swiss Federal Office of Public Health (FOPH) Levothyroxine for patients diagnosed with subclinical hypothyroidism
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: organization of care and services for the prevention and management of post COVID-19 conditions]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: helicopter emergency medical services (HEMS) - needs analysis and clientele identification]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (adenocarcinoma of the stomach, the gastro-oesophageal junction or the oesophagus) - 2nd Addendum to Commission A21-146]
2022     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Denosumab (Prolia) for the treatment of osteoporosis
2022     National Institute for Health and Care Excellence (NICE) Supercapsular percutaneously assisted total hip arthroplasty for osteoarthritis. NICE interventional procedures guidance 726
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: practices for screening or reducing psychological symptoms in individuals with a post-COVID-19 condition]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: molecular profiling of adult solid tumors - Focus Panel (Illumina) – 52 somatic biomarkers analysis]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mepolizumab (hypereosinophilic syndrome) - Addendum to Commission A21-152]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trastuzumab deruxtecan (breast cancer, HER2+, at least 2 prior therapies) - Benefit assessment according to §35a Social Code Book V]
2022     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Calcitonin gene-related peptide antagonists for the prevention of migraine [Protocol]
2022     National Institute for Health and Care Excellence (NICE) Personalised external aortic root support (PEARS) using mesh to prevent aortic root expansion and aortic dissection in people with Marfan syndrome. NICE interventional procedures guidance 724
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: primary care and service quality indicators for supporting continuous quality improvement in Québec’s family medicine groups]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: Evaluation of Fibryga (human fibrinogen concentrate) – acquired fibrinogen deficiency]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Avacopan (severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) in combination with rituximab or cyclophosphamide) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trastuzumab deruxtecan (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2022     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Oral anticoagulants for prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation. [Protocol]
2022     National Institute for Health and Care Excellence (NICE) Liposuction for chronic lymphoedema. NICE interventional procedures guidance 723
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: cervical cancer screening in Québec - recommendations for implementing the human papillomavirus detection test (HPV test) as the primary screening test]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: efficacy of psychosocial interventions for the prevention and treatment of common mental disorders and symptoms]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (combination with ivacaftor; cystic fibrosis, 6 to 11 years, F508del mutation, homozygous) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Upadacitinib (axial spondyloarthritis) - Benefit assessment according to §35a Social Code Book V]
2022     National Institute for Health and Care Excellence (NICE) Intramedullary distraction for upper limb lengthening. NICE interventional procedures guidance 722
2022     Norwegian Institute of Public Health (NIPH) Transperineal compared with transrectal biopsy on suspected prostate cancer: a health technology assessment
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: optimal use of cardiac ultrasound in Québec - diagnosing patients with a murmur and monitoring patients with valve diseases (native and prosthetic valves)]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sofosbuvir/velpatasvir (chronic hepatitis C in children 3 to < 6 years of age) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Upadacitinib (ulcerative colitis) - Benefit assessment according to §35a Social Code Book V]
2022     National Institute for Health and Care Excellence (NICE) Liposuction for chronic lipoedema. NICE interventional procedures guidance 721
2022     NIHR Health Technology Assessment programme Endovascular stent grafting and open surgical replacement for chronic thoracic aortic aneurysms: a systematic review and prospective cohort study
2022     NIHR Health Technology Assessment programme Pre-hospital and emergency department treatment of convulsive status epilepticus in adults: an evidence synthesis
2022     Ontario Health Mechanical thrombectomy for acute and subacute blocked arteries and veins in the lower limbs
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (combination with ivacaftor; cystic fibrosis, 6 to 11 years, F508del mutation, MF mutation, heterozygous) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Valoctocogene roxaparvovec (haemophilia A) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2022     National Institute for Health and Care Excellence (NICE) Percutaneous insertion of a cystic duct stent after cholecystostomy for acute calculous cholecystitis. NICE interventional procedures guidance 720
2022     Health Technology Wales (HTW) Virtual reality interventions for the management of pain associated with medical procedures
2022     Norwegian Institute of Public Health (NIPH) [Transcranial direct current stimulation for depression and aphasia. A health technology assessment]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (combination with ivacaftor; cystic fibrosis, 6 to 11 years, F508del mutation, gating mutation, heterozygous) - Benefit assessment according to §35a Social Code Book V]
2022     National Institute for Health and Care Excellence (NICE) Endoscopic full thickness removal of gastrointestinal stromal tumours of the stomach. NICE interventional procedures guidance 717
2022     NIHR Health Technology Assessment programme A large randomised assessment of the relative cost-effectiveness of different classes of drugs for Parkinson's disease (PD MED)
2022     Norwegian Institute of Public Health (NIPH) [Overdose warning systems: a single technology assessment - mapping]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (combination with ivacaftor; cystic fibrosis, 6 to 11 years, F508del mutation, RF mutation, heterozygous) - Benefit assessment according to §35a Social Code Book V]
2022     National Institute for Health and Care Excellence (NICE) Intramedullary distraction for lower limb lengthening. NICE interventional procedures guidance 718
2022     Agency for Care Effectiveness (ACE) Negative pressure wound therapy for wound management in patients with diabetes (type 1 and 2)
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (combination with ivacaftor; cystic fibrosis, 6 to 11 years, F508del mutation, other/unknown mutation, heterozygous) - Benefit assessment according to §35a Social Code Book V]
2022     National Institute for Health and Care Excellence (NICE) Endoscopic balloon dilation for subglottic or tracheal stenosis. NICE interventional procedures guidance 719
2022     NIHR Health Technology Assessment programme Telaprevir for the treatment of genotype 1 chronic hepatitis C
2022     NIHR Health Technology Assessment programme Planned early delivery or expectant management for late preterm pre-eclampsia (PHOENIX): a randomised controlled trial
2022     Agency for Care Effectiveness (ACE) Brentuximab vedotin for treating T-cell lymphoma
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sotorasib (NSCLC) - Benefit assessment according to §35a Social Code Book V]
2022     National Institute for Health and Care Excellence (NICE) Stereotactic radiosurgery for trigeminal neuralgia. NICE interventional procedures guidance 715
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for treating advanced urothelial carcinoma
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Transcervical radiofrequency ablation with intrauterine ultrasound guidance for uterine fibroids - Addendum to commission H21-14]
2022     National Institute for Health and Care Excellence (NICE) Microwave ablation for primary or metastatic cancer in the lung. NICE interventional procedures guidance 716
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: classification of thickened liquids for dysphagia]
2022     Agency for Care Effectiveness (ACE) Ruxolitinib for treating polycythaemia vera
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Implantation via injection under endoscopic ultrasound guidance of 32P-labeled microparticles for unresectable, locally advanced pancreatic tumours - Addendum to commission H21-13]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: evaluation of HyQvia™ (human normal immunoglobulin 10% and hyaluronidase) – primary and secondary immunodeficiency]
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for treating early or advanced HER2-positive breast cancer
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Brivaracetam (epilepsy in children [aged 2 to < 4 years]) - Benefit assessment according to §35a Social Code Book V]
2022     Health Information and Quality Authority (HIQA) Descriptive analysis of COVID-19 epidemiological indicators and associated contextual factors in European countries
2022     Agency for Care Effectiveness (ACE) Poly (ADP-ribose) polymerase inhibitors for treating BRCA-mutated, HER2-negative advanced breast cancer
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vedolizumab (antibiotic refractory chronic pouchitis) - Benefit assessment according to §35a Social Code Book V]
2022     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Blinatumomab (new therapeutic indication: acute lymphoblastic B-cell leukaemia, high-risk first relapse, Ph-, CD19+, ≥1 and <18 years)]
2022     Agency for Care Effectiveness (ACE) Polatuzumab vedotin for treating relapsed or refractory diffuse large B-cell lymphoma
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lorlatinib (NSCLC) - benefit assessment according to §35a Social Code Book V]